MedTrace Logo

p-AKT Expression on Clinical Outcomes in Malignant Lymphoma

NCT01789060 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 262

Last updated 2013-02-11

No results posted yet for this study

Summary

PI3K(phosphatidylinositol 3-kinase)/AKT pathway is an important oncogenic signaling pathway. However, clinical information about the significance of p-AKT expression in malignant lymphoma is not fully understood yet. In this study, we investigated the overexpression of p-AKT and its prognostic implication in malignant lymphoma.

Conditions

  • Malignant Lymphoma
  • P13K-AKT Pathway Deregulation

Interventions

OTHER

p-AKT immunohistochemical staining

p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Won Seog Kim, MD PhD · Samsung Medical Center

Eligibility

Min Age
17 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01789060 on ClinicalTrials.gov